WallStreetZenWallStreetZen

NASDAQ: THAR
Tharimmune Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their THAR stock forecasts and price targets.

Forecast return on equity

Is THAR forecast to generate an efficient return?

Company
-40.65%
Industry
29.73%
Market
329.89%
THAR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is THAR forecast to generate an efficient return on assets?

Company
-32.5%
Industry
13.26%
THAR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

THAR earnings per share forecast

What is THAR's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.07

THAR revenue forecast

What is THAR's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0

THAR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
THAR$2.99N/AN/A
AGEN$3.12$23.00+637.18%Buy
ETHZ$4.99N/AN/A
ANIX$3.12$8.50+172.44%Strong Buy
ARTV$4.18$18.67+346.58%Buy
View Top Biotech Stocks

Tharimmune Stock Forecast FAQ

What is THAR's earnings growth forecast for 2026-2026?

(NASDAQ: THAR) Tharimmune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 205.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,962.23%.

Tharimmune's earnings in 2025 is -$10,319,245.

In 2026, THAR is forecast to generate -$2,502,200 in earnings, with the lowest earnings forecast at -$2,404,074 and the highest earnings forecast at -$2,575,794.

If you're new to stock investing, here's how to buy Tharimmune stock.

What is THAR's revenue growth forecast for 2026-2026?

(NASDAQ: THAR) Tharimmune's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,251.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,437.49%.

Tharimmune's revenue in 2025 is $0.

In 2026, THAR is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is THAR's forecast return on assets (ROA) for 2026-2026?

(NASDAQ: THAR) forecast ROA is -32.5%, which is lower than the forecast US Biotechnology industry average of 13.26%.

What is THAR's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: THAR) Tharimmune's current Earnings Per Share (EPS) is -$3.99. In 2026, THAR's EPS is forecast to hit -$0.07 (min: -$0.07, max: -$0.07).

What is THAR's forecast return on equity (ROE) for 2026-2026?

(NASDAQ: THAR) forecast ROE is -40.65%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.